{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-026752","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.173029+00:00","generated_at":"2026-06-23T07:31:46.621564+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication","bullets":["Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.","Placebo group: 100% of subjects met VAS threshold for feeling high; only 1 subject per active dose group met threshold.","Safety: adverse events mild/transient except two moderate dizziness cases in Cohort 1 likely THC-attributable.","Company continuing Part B, enrolling third cohort; collaborating with FDA MIDD group on PK/PD model to optimize dosing for ACI."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-026752","json":"https://secwatch.observer/filing/0001493152-22-026752.json","markdown":"https://secwatch.observer/filing/0001493152-22-026752.md","text":"https://secwatch.observer/filing/0001493152-22-026752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/0001493152-22-026752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:31:46.621564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}